We protect your health through science
Investigation
Viral Biology
Publications
Effects of 3D nanocomposite bioceramic scaffolds on the immune response
4. Cicuendez M., Portolés P., Montes-Casado M., Izquierdo-Barba I., Vallet-Regı M., and Portolés M.T. Effects of 3D nanocomposite bioceramic scaffolds on the immune response. J. Mater. Chem. B, 2014, 2 (22), 3469-3479.
DOICharacteristics of TCR/CD3 complex CD3 chains of regulatory CD4+ T (Treg) lymphocytes: Role in Treg differentiation in vitro and impact on Treg in vivo.
5. Rojo, J. M., G. Ojeda, Y. Y. Acosta, M. Montes-Casado, G. Criado, and P. Portoles. Characteristics of TCR/CD3 complex CD3 chains of regulatory CD4+ T (Treg) lymphocytes: Role in Treg differentiation in vitro and impact on Treg in vivo. J. Leukoc. Biol. 2014, 95 (3): 441-450.
PUBMED DOIDissociation of actin polymerization and lipid raft accumulation by ligation of the Inducible Costimulator (ICOS, CD278)
6. Y. Acosta, G. Ojeda, M. P. Zafra, I. Seren-Bernardone, A. Sánchez, U. Dianzani, P. Portolés y J. M. Rojo. Dissociation of actin polymerization and lipid raft accumulation by ligation of the Inducible Costimulator (ICOS, CD278). Inmunología, 2012, 31 (1): 4-12.
DOIComplement regulatory protein Crry/p65 costimulation expands natural Treg cells with enhanced suppressive properties in proteoglycan-induced arthritis.
7. Ojeda G., Pini E., Eguiluz C., Montes-Casado M., Broere F., van Eden W., Rojo J.M., and Portolés P. Complement regulatory protein Crry/p65 costimulation expands natural Treg cells with enhanced suppressive properties in proteoglycan-induced arthritis. Arthritis Rheum. 2011 Jun;63(6):1562-72.
PUBMED DOIContent with Investigacion .
-
-
Francisco Javier Nieto Martínez
Científico titular
-
Carmen Chicharro Gonzalo
Técnico Superior Especializado de OPI
-
José Carlos Solana
Titulado Superior en prácticas
-
Laura Botana Veguilla
Titulado Superior en prácticas
-
Loren Bernardo Bernardo
Investigador predoctoral en formación
-
Emilia García Diez
Ayudante de investigación
-
Carmen Sánchez Herrero
Técnico superior contratado
-
Raquel Budejo Sancho
Técnico superior en prácticas
-
Eugenia Carrillo Gallego
Titulado Superior de Actividades Técnicas y Profesionales
-
Ana Victoria Ibarra
Titulado Superior Doctor en prácticas
List of staff
Additional Information
The research activity of the Viral Biology group since its beginnings in the 1980s has focused on respiratory viruses, especially on the study of the mechanisms of virus entry into the cell, evolutionary aspects, antigenic properties and vaccine development.
Currently, the group's objectives are focused on the characterisation of the immune response and the development of vaccines against human pneumoviruses: human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV).
Both viruses are considered to be important respiratory pathogens of high clinical relevance, especially in the paediatric population.
Safe and effective vaccines against these viruses are currently not available. Soluble protein subunits based on the fusion protein (F-protein) of hRSV and hMPV are being developed in the laboratory by protein engineering for use as vaccines against human pneumoviruses.
On the other hand, and thanks to the characterisation of the type of humoral response induced by the F proteins of these viruses, the laboratory is also involved in the isolation of monoclonal antibodies and nanoantibodies for use as treatments against these viruses.
The research activity of the Viral Biology group since its beginnings in the 1980s has focused on respiratory viruses, especially on the study of the mechanisms of virus entry into the cell, evolutionary aspects, antigenic properties and vaccine development.
Currently, the group's objectives are focused on the characterisation of the immune response and the development of vaccines against human pneumoviruses: human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV).
Both viruses are considered to be important respiratory pathogens of high clinical relevance, especially in the paediatric population.
Safe and effective vaccines against these viruses are currently not available. Soluble protein subunits based on the fusion protein (F-protein) of hRSV and hMPV are being developed in the laboratory by protein engineering for use as vaccines against human pneumoviruses.
On the other hand, and thanks to the characterisation of the type of humoral response induced by the F proteins of these viruses, the laboratory is also involved in the isolation of monoclonal antibodies and nanoantibodies for use as treatments against these viruses.